Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912583 | 0.81 | ALDH1A1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL912707 | 0.78 | POLB (0.35) | ALDH1A1MAPT | |
| SCHEMBL1434515 | 0.75 | MAPT (0.34) | TYMPMAPTCNR2 | |
| SCHEMBL19027031 | 0.64 | MAPT (0.35) | MAPTCNR2 | |
| SCHEMBL8458 | 0.59 | ALDH1A1 (0.67) | ALDH1A1 | |
| SCHEMBL9445300 | 0.58 | CYP1A2 (0.32) | MAPT | |
| SCHEMBL912638 | 0.57 | CYP1A2 (0.55) | ALDH1A1MAPTRAF1BRAF | |
| SCHEMBL5661986 | 0.57 | ALDH1A1 (0.71) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL516842 | 0.57 | ALDH1A1 (0.64) | ALDH1A1 | |
| SCHEMBL22609104 | 0.56 | ALDH1A1 (0.75) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872005-B2 | 2-substituted heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-01-18 | — | — | US | disclosed |
| US-20060063739-A1 | 2-Substituted heteroaryl compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063739-A1 | 2-Substituted heteroaryl compounds | IL2, IL4, IL2RA | TYMP 4420/4885ALDH1A1 1298/4885MAPT 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.